{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:08:42Z","timestamp":1791475722773,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.schres.2016.01.046","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T05:45:15Z","timestamp":1456465515000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)"],"prefix":"10.1016","volume":"172","author":[{"given":"Karin","family":"Landolt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf","family":"R\u00f6ssler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladeta","family":"Ajdacic-Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eske M.","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Libiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Wolfgang","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2016.01.046_bb0005","series-title":"Practice Guideline for the Treatment of Patients with Schizophrenia","author":"(APA), A.P.A.","year":"2004"},{"issue":"22","key":"10.1016\/j.schres.2016.01.046_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","author":"Addington","year":"1993","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"7","key":"10.1016\/j.schres.2016.01.046_bb0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","article-title":"Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal","volume":"22","author":"Alvarez-Jimenez","year":"2008","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.schres.2016.01.046_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2016.01.046_bb0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/schbul\/sbj019","article-title":"Medication-free research in early episode schizophrenia: evidence of long-term harm?","volume":"32","author":"Bola","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2016.01.046_bb0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.schbul.a006964","article-title":"At issue: predicting drug-free treatment response in acute psychosis from the Soteria project","volume":"28","author":"Bola","year":"2002","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.schres.2016.01.046_bb0035","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/01.nmd.0000243080.90255.88","article-title":"Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project","volume":"194","author":"Bola","year":"2006","journal-title":"J. Nerv. Ment. Dis."},{"issue":"6","key":"10.1016\/j.schres.2016.01.046_bb0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.0001-690X.2003.00207.x","article-title":"Which individuals with affective symptoms seek help? Results from the Zurich epidemiological study","volume":"108","author":"Burns","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2016.01.046_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbm047","article-title":"A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia","volume":"34","author":"Calton","year":"2008","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2016.01.046_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/schbul\/23.1.11","article-title":"The risk of medication-free research","volume":"23","author":"Carpenter","year":"1997","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2016.01.046_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1997.01830170015002","article-title":"The rationale and ethics of medication-free research in schizophrenia","volume":"54","author":"Carpenter","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"issue":"18","key":"10.1016\/j.schres.2016.01.046_bb0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1192\/S0007125000297183","article-title":"The pilot project \u2018Soteria Berne\u2019. Clinical experiences and results","author":"Ciompi","year":"1992","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"2","key":"10.1016\/j.schres.2016.01.046_bb0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/JCP.0b013e3181d2193c","article-title":"Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6weeks of nonresponse?","volume":"30","author":"Derks","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.schres.2016.01.046_bb0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","article-title":"The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial","volume":"78","author":"Fleischhacker","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.01.046_bb0075","series-title":"Handbook of Psychiatric Measures","first-page":"100","article-title":"Clinical Global Impressions (CGI) Scale","author":"Guy","year":"2000"},{"key":"10.1016\/j.schres.2016.01.046_bb0080","series-title":"Principles and Practice of Psychopharmacotherapy","author":"Janicak","year":"1997"},{"issue":"5","key":"10.1016\/j.schres.2016.01.046_bb0085","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.166.5.654","article-title":"A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF)","volume":"166","author":"Jones","year":"1995","journal-title":"Br. J. Psychiatry"},{"issue":"9618","key":"10.1016\/j.schres.2016.01.046_bb0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.schres.2016.01.046_bb0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.01.046_bb0100","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1192\/bjp.172.5.413","article-title":"Randomised controlled trial of compliance therapy. 18-Month follow-up","volume":"172","author":"Kemp","year":"1998","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.01.046_bb0105","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.npp.1301233","article-title":"Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys","volume":"32","author":"Konopaske","year":"2007","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2016.01.046_bb0110","doi-asserted-by":"crossref","first-page":"s65","DOI":"10.1192\/bjp.187.48.s65","article-title":"Integrating non-drug treatments in early schizophrenia","volume":"48","author":"Lewis","year":"2005","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"4","key":"10.1016\/j.schres.2016.01.046_bb0115","first-page":"278","article-title":"Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature","volume":"14","author":"Muench","year":"2001","journal-title":"J. Am. Board Fam. Pract."},{"issue":"5","key":"10.1016\/j.schres.2016.01.046_bb0120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1192\/bjp.167.5.589","article-title":"The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness","volume":"167","author":"Phelan","year":"1995","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.01.046_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/002076409904500102","article-title":"Application and results of the Manchester Short Assessment of Quality of Life (MANSA)","volume":"45","author":"Priebe","year":"1999","journal-title":"Int. J. Soc. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2016.01.046_bb0130","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/schbul\/sbq083","article-title":"Antipsychotic dosing: how much but also how often?","volume":"36","author":"Remington","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2016.01.046_bb0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"119","author":"Stahl","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"8","key":"10.1016\/j.schres.2016.01.046_bb0140","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"61","author":"Tschoner","year":"2007","journal-title":"Int. J. Clin. Pract."},{"issue":"5","key":"10.1016\/j.schres.2016.01.046_bb0145","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.v68n0502","article-title":"Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome","volume":"68","author":"Wunderink","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2016.01.046_bb0150","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry."},{"issue":"2\u20133","key":"10.1016\/j.schres.2016.01.046_bb0155","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2013.08.001","article-title":"Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review","volume":"152","author":"Zipursky","year":"2014","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416300469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416300469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T21:15:48Z","timestamp":1567631748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416300469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":31,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0920996416300469"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.01.046","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.01.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}